![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||
Impaired mesenchymal cell function in Gata4 mutant mice leads to diaphragmatic hernias and primary lung defects 1 Department of Pediatrics, Washington University and St. Louis Children’s Hospital, St. Louis, MO 63110 2 Department of Genetics, Washington University and St. Louis Children’s Hospital, St. Louis, MO 63110 3 Departments of Molecular Biology & Pharmacology, Washington University and St. Louis Children’s Hospital, St. Louis, MO 63110 4 Program for Developmental & Reproductive Biology, Biomedicum Helsinki and Children’s Hospital, University of Helsinki, 00290 Helsinki, Finland 5 Departments of Cardiology, Pediatrics, & Genetics, Children’s Hospital Boston and Harvard Medical School, Boston, MA 02115 Correspondence to: David B. Wilson, MD, PhD, Box 8208, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110 USA., Phone: +1.314.286.2834 FAX: +1.314.286.2892 Email: wilson_d/at/wustl.edu Abstract Congenital diaphragmatic hernia (CDH) is an often fatal birth defect that is commonly associated with pulmonary hypoplasia and cardiac malformations. Some investigators hypothesize that this constellation of defects results from genetic or environmental triggers that disrupt mesenchymal cell function in not only the primordial diaphragm but also the thoracic organs. The alternative hypothesis is that the displacement of the abdominal viscera in the chest secondarily perturbs the development of the heart and lungs. Recently, loss-of-function mutations in the gene encoding FOG-2, a transcriptional co-regulator, have been linked to CDH and pulmonary hypoplasia in humans and mice. Here we show that mutagenesis of the gene for GATA-4, a transcription factor known to functionally interact with FOG-2, predisposes inbred mice to a similar set of birth defects. Analysis of wild-type mouse embryos demonstrated co-expression of Gata4 and Fog2 in mesenchymal cells of the developing diaphragm, lungs, and heart. A significant fraction of C57Bl/6 mice heterozygous for a Gata4 deletion mutation died within one day of birth. Developmental defects in the heterozygotes included midline diaphragmatic hernias, dilated distal airways, and cardiac malformations. Heterozygotes had any combination of these defects or none. In chimeric mice, Gata4−/− cells retained the capacity to contribute to cells in the diaphragmatic central tendon and lung mesenchyme, indicating that GATA-4 is not required for differentiation of these lineages. We conclude that GATA-4, like its co-regulator FOG-2, is required for proper mesenchymal cell function in the developing diaphragm, lungs, and heart. Keywords: birth defect, diaphragm, pulmonary hypoplasia, transcription factor Introduction Congenital diaphragmatic hernia (CDH) is a severe developmental anomaly that affects 1 per 3000 live births and accounts for 1-2% of infant mortality (Pober et al., 2005; Colvin et al., 2005; Yang et al., 2006). The hallmark of the disorder is a defect in the muscular or tendinous portion of the diaphragm. CDH is thought to result from abnormal embryonic development of the diaphragmatic substratum, but the molecular pathogenesis of this disorder is poorly understood (Greer et al., 2000b; Babiuk and Greer, 2002). Primary defects in lung morphogenesis and cardiovascular malformations often accompany CDH in animal models and patients (Migliazza et al., 1999; Losty et al., 1999; Graziano, 2005). This association has given rise to the mesenchymal hit hypothesis, which posits that genetic or environmental triggers of CDH disrupt the function of mesenchymal cells in not only the primordial diaphragm but also the developing lungs and heart (Keijzer et al., 2000). A corollary, the smooth muscle hypothesis, proposes that disruption of mesenchymal progenitors of smooth muscle in the pulmonary vasculature and airways leads to pulmonary hypertension, airway hyperreactivity, and other pulmonary complications commonly encountered in patients with CDH (Jesudason, 2006). Consequently, a major goal of CDH research is to identify genes critical for early mesenchymal cell function in the diaphragm, lungs, and cardiovascular system. Recent studies, including analysis of recurring chromosomal rearrangements in patients with CDH (Lurie, 2003), suggest that transcription factor haploinsufficiency may cause or contribute to this disorder. Chromosome 8q22-23 abnormalities have been associated with CDH (Wilson et al., 1983; Temple et al., 1994; Howe et al., 1996), and mutation of one of the genes in this region, FOG2, has been shown to cause diaphragmatic defects and primary pulmonary hypoplasia in humans and mice (Ackerman et al., 2005). FOG2 encodes a transcriptional co-regulator that is expressed by mesenchymal cells in the diaphragm, lung, and heart and by somatic cells in the testis (Svensson et al., 2000; Tevosian et al., 2000; Ketola et al., 2002; Ackerman et al., 2005). Another recurring chromosomal abnormality in CDH is microdeletion of 8p23.1 (Pecile et al., 1990; Faivre et al., 1998; Borys and Taxy, 2004; Shimokawa et al., 2005; Barber et al., 2005; López et al., 2006). One of the genes in the critical region of 8p23.1 is GATA4, which encodes a transcription factor that physically interacts with FOG-2 during morphogenesis of the heart and testis (Crispino et al., 2001; Tevosian et al., 2002). It is therefore plausible that GATA4 haploinsufficiency contributes to the pathogenesis of CDH, particularly in patients with concomitant diaphragm and heart defects, as loss-of-function mutations in GATA4 have been linked to cardiac malformations in humans (Garg et al., 2003; Okubo et al., 2004; Nemer et al., 2006) and mice (Kuo et al., 1997; Molkentin et al., 1997; Crispino et al., 2001; Watt et al., 2004; Pu et al., 2004; Zeisberg et al., 2005; Xin et al., 2006). Here we show that C57Bl/6 mice heterozygous for a mutant allele of Gata4 are predisposed to CDH and primary lung abnormalities. We propose that GATA-4, working in concert with FOG-2 or other transcription factors, regulates mesenchymal cell function in the developing diaphragm and lungs. Our findings support the premise that GATA-4 mutation contributes to the pathogenesis of CDH and related developmental anomalies in man. Materials and Methods Experimental mice Procedures involving mice were approved by institutional committees for laboratory animal care and were conducted in accordance with NIH and EU guidelines for the care and use of experimental animals. C57Bl/6 and Rosa26 (C57Bl/6, Gpi-1b) (Friedrich and Soriano, 1991) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Gata4+/Δex2 mice, which harbor a deletion in exon 2 of the gene, were generated and genotyped as described elsewhere (Pu et al., 2004; Zeisberg et al., 2005). These mice were backcrossed with C57Bl/6 mice for a minimum of 7 generations. Nkx2-5+/− mice were prepared and genotyped as described previously (Tanaka et al., 2002) and were backcrossed with C57BL/6 mice for a minimum of 12 generations. Chimeric mice were prepared by injection of XYGata4−/− ES cells (CCE, 129/Sv//Ev, Gpi-1c) ES cells (Soudais et al., 1995; Kuo et al., 1997) into Rosa26 embryos as described (Narita et al., 1997a). These nullizygous ES cells harbor a neomycin resistance cassette in exon 2 of the gene. Chimeras were initially identified by GPI-1 isoenzyme analysis of tail tissue (Narita et al., 1997a). XIST RT-PCR analysis of tail or hind limb tissue was used to distinguish chimeras derived from XX versus XY host blastocysts (Natoli et al., 2004). Only chimeric mice derived from XY hosts were subjected to further analysis. Tissue isolation and histological analyses Late gestation fetuses were harvested, fixed overnight in 4% paraformaldehyde in PBS, and embedded in paraffin for routine histology. In some cases, pregnant females were injected intraperitoneally with 2 mg bromodeoxyuridine (BrdU) 15 hr before embryo harvest. Alternatively, unfixed fetuses were embedded directly in Tissue-Tek OCT compound (Sakura Finetek, Torrence, CA) for preparation of cryosections. Thoraces of newborn pups were isolated by decapitation and transection at the level of the liver. Skin and soft tissue were removed, and the intact thorax was fixed for 1-2 days in 4% paraformaldehyde ± 1% glutaraldehyde in PBS at 4°C. Diaphragm, heart, and lungs were then dissected and processed for morphometric and ultrastructural analyses. Paraffin sections (5-6 μm) were stained with hematoxylin and eosin (H&E) or with Masson’s trichrome to visualize extracellular matrix (ECM). To detect β-galactosidase (β-gal) expression, frozen tissue sections (10 μm) were fixed with 0.2% gluteraldehyde for 5 min, permeabilized with 100 mM potassium phosphate pH 7.4, 0.02% NP-40 and 0.01% sodium deoxycholate for 5-15 min, and then incubated in 0.5 mg/ml X-gal (Promega) with 10 mM K3[Fe(CN)6], 10 mM K4[Fe(CN)6], 100 mM potassium phosphate pH 7.4, 0.02% NP-40 and 0.01% sodium deoxycholate at 30°C overnight (Narita et al., 1997a). The sections were then counterstained with eosin. Morphometric analysis Air space size was estimated from the mean chord length of the airspace (Ray et al., 1997). Images of H&E stained lung tissue from postnatal day 1 mice were acquired at 400x magnification using an Olympus BX60 microscope and a Zeiss Axiocam digital camera and superimposed on a grid (Ray et al., 1997). The length of the lines overlying air space air measured using Scion® Image software and then averaged to obtain the mean chord length. Fields containing large airways and vessels were excluded from the chord length measurements. The number of bronchioles and arteries per mm2 were quantified as described elsewhere (Mäki et al., 2005). Electron microscopy Excised tissue was processed for electron microscopy as described (Narita et al., 1997a). Briefly, paraformaldehyde/glutaraldehyde-fixed tissue was treated with OsO4, and then embedded in resin. Sections (1 μm) were cut and stained with methylene blue for preliminary light microscopic evaluation. Ultrathin sections were cut, stained with uranyl acetate and lead citrate, and then examined in a JEM 1010 transmission electron microscope. Immunostaining Paraformaldehyde-fixed, paraffin-embedded tissue sections were processed for immunoperoxidase staining using previously described methods (Bielinska et al., 2005; Jacobsen et al., 2005). The following primary antibodies were employed: 1) goat anti-mouse GATA-4 IgG (sc-1237, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 1:200 dilution; 2) goat anti-mouse FOG-2 (sc-9264, Santa Cruz Biotechnology, Inc.), 1:100 dilution; 3) rabbit anti-mouse smooth muscle α-actin (AnaSpec, Inc., San Jose, CA), 1:1000 dilution; 4) rabbit anti-mouse Clara cell secretory protein CC10 (sc-25555, Santa Cruz Biotechnology, Inc.), 1:100 dilution; 5) goat anti-mouse surfactant protein C (sc-7706, Santa Cruz Biotechnology, Inc.), 1:200 dilution; 6) goat anti-phosphohistone H3 (sc-12927, Santa Cruz Biotechnology, Inc.), 1:200 dilution; and 7) mouse anti-BrdU (sc-32323, Santa Cruz Biotechnology, Inc.), 1:200 dilution. Secondary antibodies employed for immunoperoxidase staining were: donkey anti-goat biotinylated IgG (Jackson Immunoresearch, West Grove, PA) 1:1000 dilution; donkey anti-mouse biotinylated IgG (Jackson Immunoresearch), 1:2000 dilution; goat anti-rabbit biotinylated IgG (NEF-813, NEN Life Science, Boston MA), 1:2000 dilution. The avidin-biotin immunoperoxidase system (Vectastain Elite ABC Kit, Vector Laboratories, Inc., Burlingame, CA) and diaminobenzidine (Sigma-Aldrich Corp., St. Louis, MO) were used to visualize the bound antibody; slides were then counterstained with hematoxylin. In situ DNA 3′-end labeling Apoptosis was quantified in the embryonic diaphragm using an in situ thymidine deoxyribose-mediated deoxy-UTP nick end labeling (TUNEL) DNA 3′-end labeling kit (Oncor, Gaithersburg, MD). Paraformaldehyde-fixed paraffin sections were rehydrated through an alcohol series. The permeability of the cell membranes was increased by incubating the sections in 400 μg proteinase K (Roche Molecular Biochemicals, Mannheim, Germany) in 200 ml PBS for 15 min. Endogenous peroxidase activity was inhibited by quenching the samples for 5 min in 5% hydrogen peroxide. DNA fragmentation was identified by applying terminal transferase enzyme with digoxigenin-labeled nucleotides to the samples and incubating for 1 h under coverslips. Antidigoxigenin antibody was used to recognize the digoxigenin-labeled nucleotide chains attached to the 3′-ends of sample DNA. A color reaction was produced with diaminobenzidine in the presence of 0.03% hydrogen peroxide. The tissue sections were counterstained with hematoxylin. RT-PCR Lung tissue was homogenized in TRIzol (Invitrogen, Carlsbad, CA). Purified RNA (200 ng) was subjected to RT-PCR using a TITANIUM™ one-step kit (BD Biosciences, Palo Alto, CA), oligo(dT) primers for the reverse transcriptase reaction, and the PCR primers were as follows: 1) wild-type Gata4-specific; forward 5′-gaagctgcagcctacggcagt-3′, reverse 5′-gcgcatgtcttcactgctgc-3′, 707 bp; 2) Gata4Δ-specific; forward 5′-tgtcattcttcgctggagcc-3′, reverse 5′-gcgcatgtcttcactgctgc-3′, 761 bp; Gata6; forward 5′-gcaatgcatgcggcttctac-3′, reverse 5′-ctcttggtagcaccagctca-3′, 554 bp (Johnsen et al., 2006). Gapdh primers are published elsewhere (Xin et al., 2006). Agarose gel electrophoresis (1.2%) in the presence of ethidium bromide demonstrated a single band of the expected size for each of the PCR primer pairs. Authenticity of the PCR products was confirmed by direct DNA sequencing. Results Gata4 is expressed in early mesenchymal cells of the diaphragm, lungs, and great vessels We delineated the developmental expression of GATA-4 protein and mRNA in the diaphragm, lungs, and cardiovascular system of wild-type mice. Between embryonic day 11.5 (E11.5) and E15.5, intense GATA-4 immunoreactivity was evident in tissues critical for diaphragm formation (Greer et al., 2000b), including the septum transversum (and its derivative the central tendon), pleuroperitoneal folds (PPF), and esophageal mesenchyme (Fig 1A,B
Expression of GATA-4 in the diaphragm and lungs decreased at later stages of development. By postnatal day 1 (P1), only ~50% of the cells in the central tendon exhibited GATA-4 immunoreactivity (principally those lining the surface of the tendon; Fig 1F
Thus, GATA-4, like its co-regulator FOG-2, is expressed in mesenchymal and mesothelial cells of the diaphragm and lungs during the embryonic development of these organs. This pattern of expression implies that GATA-4 could play a functional role in organogenesis of not only the heart (Crispino et al., 2001; Watt et al., 2004; Pu et al., 2004; Zeisberg et al., 2005; Xin et al., 2006) but also the diaphragm and lungs. Neonatal deaths among C57Bl/6 mice heterozygous for a Gata4 deletion mutation Gata4 null mice derived from either heterozygote matings (Kuo et al., 1997; Molkentin et al., 1997) or through diploid/tetraploid complementation of Gata4−/− ES cells (Narita et al., 1997b; Watt et al., 2004) die by E10, so insights into diaphragm or lung development cannot be ascertained from these animals. We found that ~40% of C57Bl/6 mice harboring a single copy of a Gata4 mutant allele died within one day of birth, irrespective of gender (Fig 3
Among newborn offspring of Gata4+/Δex2 matings, the ratio of wild type mice to heterozygotes did not deviate from the expected Mendelian ratio of 1:2. Thus, Gata4 heterozygosity did not appear to be associated with a high rate of intrauterine demise on this genetic background. Pathological analysis of Gata4+/Δex2 mice, including healthy-appearing adults, revealed developmental anomalies in the diaphragm, lungs, and heart. The prevalence of these birth defects in 14 consecutive heterozygotes is summarized in Fig 4
Expression of normal and variant Gata4 transcripts in the heterozygotes To confirm a reduction in Gata4 expression in the heterozygotes, we performed semi-quantitative RT-PCR on samples of embryonic lung using PCR primers that were specific for the wild-type allele. The level of wild-type Gata4 mRNA in the lungs of E14.5 Gata4+/Δex2 mice was 51% that of littermate controls (P < 0.05, two-tailed t-test), whereas the level of Gata6 mRNA in the lungs of heterozygotes was similar to that of controls (Fig 5A,B
Using RT-PCR, we found that the Gata4Δex2 allele was transcribed in embryonic (E13.5-E14.5) but not newborn lung (Fig 5A,C Diaphragmatic defects in Gata4+/Δex2 mice Diaphragmatic hernias were observed in neonatal and adult Gata4 heterozygotes. The hernias arose in the ventral midline and allowed abdominal viscera (liver and gallbladder) to protrude into the thoracic cavity (Fig 6A
Among Gata4 heterozygotes the overall incidence of diaphragmatic defects (frank herniation or aberrant fusion of central tendon to liver documented on histological sections) was 6/21 (29%). Overt herniation was seen in 3/21 (14%). No diaphragmatic defects were observed on gross or histological inspection of Gata4+/+ littermate controls (n = 15; P < 0.05, two-population proportions test). Nor were diaphragmatic hernias observed on gross inspection of a larger number of unrelated wild-type C57Bl/6 mice (n = 54; ages P116-P766; P < 0.05) or C57Bl/6 mice heterozygous deficient in another cardiac transcription factor, Nkx2-5 (n = 87; ages P140-P373; P < 0.01). Reduced expression of Gata4 has been associated with increased apoptosis and impaired cellular proliferation in the heart and other tissues (Suzuki and Evans, 2004; Aries et al., 2004). TUNEL staining of E13.5 embryos showed increased apoptosis in the amuscular diaphragm of Gata4+/Δex2 mice compared to littermate controls (Fig 7B vs. A
We conclude that heterozygosity for the Gata4 deletion mutation predisposes ex2 C57Bl/6 mice to develop diaphragmatic hernias in the ventral midline. Gata4 heterozygosity does not impair cell proliferation but leads to increased apoptosis of cells in the amuscular diaphragm, which may contribute to the development of diaphragmatic hernias. Pulmonary abnormalities in Gata4+/Δex2 mice On gross inspection the lungs of Gata4+/Δex2 mice (ages E16.5-P60) resembled control lungs in overall dimensions and lobation pattern. Internally, however, dilated distal airways and patches of thickened mesenchyme were observed in the lungs of some newborn heterozygotes (Fig 8A vs. B
To determine the impact of Gata4Δex2 heterozygosity on the differentiation of endodermal and mesodermal lineages, we performed electron microscopy and immunostaining on lungs from newborn Gata4+/Δex2 mice and wild-type controls. Ultrastructural analysis showed that proximal airways in Gata4+/Δex2 lungs were lined by normal appearing Clara cells and ciliated cells (Fig 8C Expression of smooth muscle α-actin (α-SMA) in pulmonary arteries and airway smooth muscle was similar in wild type mice (Fig 9A
In summary, Gata4+/Δex2 mice are predisposed to distal airway dilatation and specific alterations in pulmonary gene expression, affecting both endoderm and mesoderm derivatives. The presence of ectopic α-SMA expression in Gata4+/Δex2 lungs suggests that GATA-4 might directly or indirectly function as a repressor of certain genes. Since some Gata4 heterozygotes exhibited lung defects in the absence of CDH (Fig 5 Absence of GATA-4 does not block mesenchymal cell differentiation in the diaphragm or lung As noted above, Gata4−/− embryos exhibit severe malformations on both pure (129 or C57Bl/6) and mixed (129:C67Bl/6) genetic backgrounds (Kuo et al., 1997; Molkentin et al., 1997; Narita et al., 1997b; Watt et al., 2004). We therefore wondered whether Gata4−/− progenitors might exhibit a block in early mesenchymal cell differentiation regardless of genetic background. To test this possibility, we generated chimeric mouse embryos by injecting Gata4−/− ES cells (129/Sv//Ev) into Rosa26 (C57BL/6) embryos. Both copies of the Gata4 gene in these ES cells bear a neomycin resistance cassette, which abrogates mRNA expression (Soudais et al., 1995; Kuo et al., 1997). Rosa26 mice bear a ubiquitously expressed β-gal transgene that facilitates lineage tracing (Friedrich and Soriano, 1991). Nullizygous ES cells retained the capacity to contribute to the central tendon of E14.5 chimeras, as demonstrated by X-gal staining (Fig 10A
We did not observe diaphragmatic hernias or overt lung anomalies among chimeric embryos (n = 7, 25-60% chimerism by GPI isozyme analysis). High percentage Gata4−/− chimeras do not survive to term (Narita et al., 1997a; Narita et al., 1997b; Watt et al., 2004), precluding an analysis of the impact of GATA-4 absence on postnatal diaphragm or lung development. Based on analysis of fetal chimeras, we conclude that GATA-4 is not essential for differentiation of mesenchymal cells in the diaphragm or lungs. Discussion Despite advances in antenatal diagnosis, surgical techniques, and medical management, the morbidity and mortality associated with CDH remain substantial (Colvin et al., 2005; Smith et al., 2005). Approximately half of the patients die in the neonatal period, and survivors often have longstanding cardiopulmonary dysfunction (West and Wilson, 2005). Although theoretically promising, fetal surgery has not been shown to improve outcome for infants with this condition. Consequently, a major focus of ongoing CDH research is on disease prevention, which mandates a better understanding of its pathogenesis. As with other developmental defects, our ability to characterize the molecular basis of CDH is dependent on animal models, and the most widely used is exposure of fetal rodents to nitrofen (Greer et al., 2000a). Diaphragmatic hernias have been observed in several genetically engineered mouse strains, including those with germline homozygous mutations of Wt1 (Kreidberg et al., 1993; Moore et al., 1998; Moore et al., 1999), Slit3 (Yuan et al., 2003; Liu et al., 2003), the Slit receptor Robo1 (Xian et al., 2001), Fog2 (Ackerman et al., 2005), or Lox (Mäki et al., 2002; Hornstra et al., 2003; Mäki et al., 2005). More recently, conditional mutagenesis of Coup-TFII in the foregut mesentery and PPF has been shown to cause CDH in mice (You et al., 2005). Supporting the mesenchymal hit hypothesis, some of these mouse strains predisposed to CDH have attendant defects in the lungs or heart. We describe here a novel mouse model of CDH based on heterozygosity of a Gata4 deletion mutation. Like other genes implicated in CDH, Gata4 is expressed in the embryonic structures that fuse to form the diaphragm. Gata4+/Δex2 mice develop midline diaphragmatic hernias resembling those seen in Slit3−/− mice (Yuan et al., 2003; Liu et al., 2003). Increased apoptosis in the diaphragmatic substratum of the heterozygotes (Fig 7 In addition to CHD, Gata4+/Δex2 mice are predisposed to primary pulmonary developmental defects, including dilated distal airspaces, impaired (or delayed) expression of airway epithelial markers, and ectopic expression of α-SMA in mesothelium. Proper lung development requires coordinated interactions between endoderm-derived airway epithelial cells and mesodermal derivatives (mesothelium, submesothelial mesenchyme, subepithelial mesenchyme, etc.) (Shannon and Hyatt, 2004; Borok et al., 2006; White et al., 2006). Since pulmonary expression of GATA-4 is restricted to mesodermal derivatives, the airway defects in Gata4 heterozygotes are presumably the indirect effects of perturbed signaling from mesenchyme or mesothelium to endoderm. Similar abnormalities in airway development have been observed in mice deficient in certain ECM proteins, including elastin (Wendel et al., 2000), lysyl oxidase (Mäki et al., 2005), fibulin-4 (McLaughlin et al., 2006), fibulin-5 (Yanagisawa et al., 2002), laminin α5 (Nguyen et al., 2005), and laminin γ2 (Nguyen et al., 2006), and in mice deficient in the transcription factors Foxf1 (Mahlapuu et al., 2001; Kalinichenko et al., 2004), FOG-2 (Ackerman et al., 2005), and p300 (Shikama et al., 2003). In several of these cases, lung abnormalities were more pronounced in the middle and accessory lobes of the right lung. Phenotypic similarities between Fog2−/− (Ackerman et al., 2005) and Gata4+/Δex2 mice suggest that the main activity affected by FOG-2 deficiency in the diaphragm and lungs is GATA-4 rather than another GATA factor. Supporting this premise, a recent abstract (Ackerman et al., 2006) reported primary defects in lung development in mice harboring a Gata4 missense mutation that disrupts GATA4-FOG interactions; the pulmonary phenotype of these Gata4 missense mutants resembled that of Fog2−/− mice. Traditionally GATA-6, a factor expressed in pulmonary epithelium, has been viewed as the sole member of the GATA family required for lung morphogenesis (Keijzer et al., 2001; Yang et al., 2002); it is now apparent that GATA-4 also influences pulmonary development through its expression in mesodermal cells. Our observations connecting murine Gata4 mutations to CDH and related developmental anomalies are consistent with other lines of evidence. First, microdeletions spanning the human GATA4 gene on 8p23.1 have been linked to cases of CHD, including cases associated with cardiac malformations typical of GATA4 haploinsufficiency (Faivre et al., 1998; Devriendt et al., 1999; Shimokawa et al., 2005; Barber et al., 2005). In fact, most reported cases of CDH in del(8)(p22.1-pter) had an accompanying cardiac malformation, especially atrioventricular canal defects (Lurie, 2003). Indeed, it has been suggested that deletion 8p23.1 should be considered whenever the combination of diaphragmatic hernia and AV canal is encountered (Faivre et al., 1998). Second, the expression and activity of GATA-4 are influenced by retinoids (Arceci et al., 1993; Kostetskii et al., 1999; Clabby et al., 2003; Ghatpande et al., 2006), and perturbed retinoid metabolism has been linked to malformations of the diaphragm, lungs, and heart (reviewed in Greer et al., 2003; Gallot et al., 2005; Montedonico et al., 2006). Ultimate proof that GATA-4 is involved in the pathogenesis of human CDH awaits the identification of patients with diaphragmatic hernias and small deletions or point mutations within the GATA4 gene. Given the established role of GATA-4 in heart and testis development, such patients with CDH might be predicted to have concomitant cardiac malformations (Pehlivan et al., 1999; Garg et al., 2003; Okubo et al., 2004) or male-to-female sex reversal (Meacham et al., 1991; Maaswinkel-Mooij and Stokvis-Brantsma, 1992; Manouvrier-Hanu et al., 2000; Killeen et al., 2002; Kent et al., 2004). Our findings, coupled with those of other investigators (Kreidberg et al., 1993; Ackerman et al., 2005; You et al., 2005), suggest that proper development of the diaphragm requires the concerted action of several transcription factors, including GATA-4, FOG-2, COUP-TFII and WT-1. We speculate that these factors regulate a set of genes critical for mesenchymal cell function in the diaphragmatic substratum as well as the lungs and heart. Preliminary analysis of Fog2−/− mouse embryos suggests that the hepatocyte growth factor gene may be one of the targets (Ackerman et al., 2005). Whatever the target genes are, we note that they may be abnormally expressed in some but not all affected animals or even within the cells or tissues of the same animal, as shown, for example, by the random ectopic expression of α-SMA in regions of the pleura of some Gata4 heterozygotes. The molecular mechanism of stochastic gene expression is unknown but could underlie the ostensibly random combination of diaphragm, lung and heart defects in mutant animals and human patients. Earlier studies of Gata4 heterozygous deficient mice failed to detect CDH or any other obvious birth defect (Kuo et al., 1997; Molkentin et al., 1997; Watt et al., 2004), although Gata4 heterozygotes have been shown to have increased sensitivity to doxorubicin-induced cardiotoxicity (Aries et al., 2004). Differences in genetic background probably impact the development of birth defects in Gata4 heterozygotes, since previous studies employed mixed backgrounds (Kuo et al., 1997; Molkentin et al., 1997) rather than a C57Bl/6 “congenic” strain. The Gata4 loss-of-function allele used here (Gata4Δex2) differs from that used in other studies (Kuo et al., 1997; Molkentin et al., 1997; Watt et al., 2004; Aries et al., 2004), so allele-specific effects might account for some of the findings. We postulate that epigenetic influences and stochastic events contribute to the phenotypic variability in the Gata4Δex2 heterozygotes on the C57Bl/6 background (Cook et al., 1998; Magee et al., 2003). This incomplete penetrance may be exploited for future mechanistic studies; C57Bl/6 Gata4+/Δex2 mice may serve as a “sensitized” strain that is useful for probing the effects of vitamin A deficiency, teratogens, and modifier genes on the development of CDH and related anomalies. Acknowledgments We thank Karen Hutton in the DDRCC Histology Core for her assistance. We thank Brian Hackett for helpful discussions. This research was supported by NIH HL61006 & DK52574, MOD FY02-203, Mallinckrodt Foundation, Finnish Pediatric Research Foundation, and the Juselius Foundation. PYJ is a Scholar of the Child Health Research Center of Excellence in Developmental Biology at Washington University School of Medicine (K12-HD001487). Footnotes Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Reference List
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||
Am J Med Genet A. 2005 Oct 1; 138A(2):81-8.
[Am J Med Genet A. 2005]Pediatrics. 2005 Sep; 116(3):e356-63.
[Pediatrics. 2005]Birth Defects Res A Clin Mol Teratol. 2006 Mar; 76(3):170-4.
[Birth Defects Res A Clin Mol Teratol. 2006]J Appl Physiol. 2000 Dec; 89(6):2123-9.
[J Appl Physiol. 2000]Am J Physiol Lung Cell Mol Physiol. 2002 Dec; 283(6):L1310-4.
[Am J Physiol Lung Cell Mol Physiol. 2002]J Pediatr Surg. 1999 Sep; 34(9):1352-8.
[J Pediatr Surg. 1999]J Pediatr Surg. 1999 Aug; 34(8):1203-7.
[J Pediatr Surg. 1999]J Pediatr Surg. 2005 Jun; 40(6):1045-9; discussion 1049-50.
[J Pediatr Surg. 2005]Am J Pathol. 2000 Apr; 156(4):1299-306.
[Am J Pathol. 2000]J Pediatr Surg. 2006 Feb; 41(2):431-5.
[J Pediatr Surg. 2006]Genet Couns. 2003; 14(1):75-93.
[Genet Couns. 2003]Am J Dis Child. 1983 May; 137(5):444-8.
[Am J Dis Child. 1983]J Med Genet. 1994 Sep; 31(9):735-7.
[J Med Genet. 1994]Prenat Diagn. 1996 Nov; 16(11):1003-9.
[Prenat Diagn. 1996]PLoS Genet. 2005 Jul; 1(1):58-65.
[PLoS Genet. 2005]Genes Dev. 1991 Sep; 5(9):1513-23.
[Genes Dev. 1991]Dev Biol. 2004 Nov 1; 275(1):235-44.
[Dev Biol. 2004]J Clin Invest. 2005 Jun; 115(6):1522-31.
[J Clin Invest. 2005]Cold Spring Harb Symp Quant Biol. 2002; 67():317-25.
[Cold Spring Harb Symp Quant Biol. 2002]Development. 1995 Nov; 121(11):3877-88.
[Development. 1995]J Clin Invest. 1997 Nov 15; 100(10):2501-11.
[J Clin Invest. 1997]Am J Pathol. 2005 Oct; 167(4):927-36.
[Am J Pathol. 2005]Dev Dyn. 2005 Oct; 234(2):355-62.
[Dev Dyn. 2005]J Endocrinol. 2006 Jul; 190(1):47-57.
[J Endocrinol. 2006]Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11189-94.
[Proc Natl Acad Sci U S A. 2006]J Appl Physiol. 2000 Dec; 89(6):2123-9.
[J Appl Physiol. 2000]Development. 2001 Feb; 128(4):503-11.
[Development. 2001]Development. 2002 May; 129(9):2233-46.
[Development. 2002]Genes Dev. 2001 Apr 1; 15(7):839-44.
[Genes Dev. 2001]Proc Natl Acad Sci U S A. 2004 Aug 24; 101(34):12573-8.
[Proc Natl Acad Sci U S A. 2004]Dev Biol. 2004 Nov 1; 275(1):235-44.
[Dev Biol. 2004]J Clin Invest. 2005 Jun; 115(6):1522-31.
[J Clin Invest. 2005]Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11189-94.
[Proc Natl Acad Sci U S A. 2006]Genes Dev. 1997 Apr 15; 11(8):1048-60.
[Genes Dev. 1997]Genes Dev. 1997 Apr 15; 11(8):1061-72.
[Genes Dev. 1997]Dev Biol. 1997 Sep 15; 189(2):270-4.
[Dev Biol. 1997]Proc Natl Acad Sci U S A. 2004 Aug 24; 101(34):12573-8.
[Proc Natl Acad Sci U S A. 2004]Dev Biol. 2004 Nov 1; 275(1):235-44.
[Dev Biol. 2004]Mol Cell Biol. 1993 Apr; 13(4):2235-46.
[Mol Cell Biol. 1993]Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5217-22.
[Proc Natl Acad Sci U S A. 2003]Mech Dev. 2003 Sep; 120(9):1059-70.
[Mech Dev. 2003]Life Sci. 2004 Feb 27; 74(15):1829-38.
[Life Sci. 2004]Proc Natl Acad Sci U S A. 2004 May 4; 101(18):6975-80.
[Proc Natl Acad Sci U S A. 2004]J Clin Invest. 1997 Nov 15; 100(10):2501-11.
[J Clin Invest. 1997]EMBO J. 2003 Oct 1; 22(19):5175-85.
[EMBO J. 2003]J Biol Chem. 2001 Oct 5; 276(40):37178-85.
[J Biol Chem. 2001]Genes Dev. 1997 Apr 15; 11(8):1048-60.
[Genes Dev. 1997]Genes Dev. 1997 Apr 15; 11(8):1061-72.
[Genes Dev. 1997]Dev Biol. 1997 Sep 15; 189(2):270-4.
[Dev Biol. 1997]Proc Natl Acad Sci U S A. 2004 Aug 24; 101(34):12573-8.
[Proc Natl Acad Sci U S A. 2004]Development. 1995 Nov; 121(11):3877-88.
[Development. 1995]Dev Biol. 1997 Sep 15; 189(2):270-4.
[Dev Biol. 1997]Proc Natl Acad Sci U S A. 2004 Aug 24; 101(34):12573-8.
[Proc Natl Acad Sci U S A. 2004]Pediatrics. 2005 Sep; 116(3):e356-63.
[Pediatrics. 2005]Arch Dis Child. 2005 Apr; 90(4):426-8.
[Arch Dis Child. 2005]Semin Perinatol. 2005 Apr; 29(2):129-33.
[Semin Perinatol. 2005]Pediatr Pulmonol. 2000 May; 29(5):394-9.
[Pediatr Pulmonol. 2000]Cell. 1993 Aug 27; 74(4):679-91.
[Cell. 1993]Mech Dev. 1998 Dec; 79(1-2):169-84.
[Mech Dev. 1998]Development. 1999 May; 126(9):1845-57.
[Development. 1999]Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5217-22.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5217-22.
[Proc Natl Acad Sci U S A. 2003]Mech Dev. 2003 Sep; 120(9):1059-70.
[Mech Dev. 2003]Theor Biol Med Model. 2006 Feb 17; 3():9.
[Theor Biol Med Model. 2006]Annu Rev Physiol. 2004; 66():625-45.
[Annu Rev Physiol. 2004]Development. 2006 Apr; 133(8):1507-17.
[Development. 2006]Am J Respir Cell Mol Biol. 2000 Sep; 23(3):320-6.
[Am J Respir Cell Mol Biol. 2000]Am J Pathol. 2005 Oct; 167(4):927-36.
[Am J Pathol. 2005]Mol Cell Biol. 2006 Mar; 26(5):1700-9.
[Mol Cell Biol. 2006]PLoS Genet. 2005 Jul; 1(1):58-65.
[PLoS Genet. 2005]Development. 2001 Feb; 128(4):503-11.
[Development. 2001]Development. 2002 May; 129(9):2233-46.
[Development. 2002]Prenat Diagn. 1998 Oct; 18(10):1055-60.
[Prenat Diagn. 1998]Am J Hum Genet. 1999 Apr; 64(4):1119-26.
[Am J Hum Genet. 1999]Am J Med Genet A. 2005 Jul 1; 136(1):49-51.
[Am J Med Genet A. 2005]Eur J Hum Genet. 2005 Oct; 13(10):1131-6.
[Eur J Hum Genet. 2005]Genet Couns. 2003; 14(1):75-93.
[Genet Couns. 2003]Cell. 1993 Aug 27; 74(4):679-91.
[Cell. 1993]PLoS Genet. 2005 Jul; 1(1):58-65.
[PLoS Genet. 2005]Proc Natl Acad Sci U S A. 2005 Nov 8; 102(45):16351-6.
[Proc Natl Acad Sci U S A. 2005]Genes Dev. 1997 Apr 15; 11(8):1048-60.
[Genes Dev. 1997]Genes Dev. 1997 Apr 15; 11(8):1061-72.
[Genes Dev. 1997]Proc Natl Acad Sci U S A. 2004 Aug 24; 101(34):12573-8.
[Proc Natl Acad Sci U S A. 2004]Proc Natl Acad Sci U S A. 2004 May 4; 101(18):6975-80.
[Proc Natl Acad Sci U S A. 2004]Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15641-6.
[Proc Natl Acad Sci U S A. 1998]Cancer Cell. 2003 Mar; 3(3):273-83.
[Cancer Cell. 2003]